This Is By Far My #1 Income Stock

This is a must read. If you cannot see this email properly, please click [here]( Dear Reader, I am often asked what my favorite dividend stock is. So I want to share the [one single stock]( that's by far my favorite right now. Unlike many dividend-paying companies... which rely on boring income through utilities, rent or oil... [This company]( owns the bestselling drug in the world, which brought in $19.9 billion in revenue last year. And it has a pipeline of other blockbuster drugs, which are expected to generate $35 billion in sales. It doesn't take a genius to know that healthcare is at the forefront of everyone's mind right now, including the folks on Wall Street. Last year, this company's stellar drug sales allowed it to pay shareholders $5.6 billion in dividends. That's cash you can claim a piece of. And today, I want to give you the name, the ticker symbol and my full analysis completely free - no strings attached. [Click here to get it.]( Sincerely, Marc Lichtenfeld Chief Income Strategist, The Oxford Club P.S. When I say FREE, I mean it. There is no catch. You get my entire Ultimate Dividend Package... including my No. 1 dividend stock... free of charge. [Here's how.]( [dividend bundle]( This ad is sent on behalf of The Oxford Club. 105 W Monument St, Baltimore, Maryland 21201. If you would like to optout from receiving offers from The Oxford Club please [click here](. MarketSectorDaily.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be third-party advertisements where the advertiser is paying per click, per lead, or per sale and are not endorsed or warranted by our staff or company. SPMG, MarketSectorDaily.com and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged not to use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. SPMG, MarketSectorDaily.com nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from SPMG or MarketSectorDaily.com to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketSectorDaily.com MarketSectorDaily.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Mt. Mourne | North Carolina | 28123 | United States | 8774119808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software